For the quarter ended June 2025, Inspire Medical Systems (INSP) reported revenue of $217.09 million, up 10.8% over the same period last year. EPS came in at $0.45, compared to $0.32 in the year-ago quarter.
The reported revenue represents a surprise of +0.95% over the Zacks Consensus Estimate of $215.05 million. With the consensus EPS estimate being $0.22, the EPS surprise was +104.55%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Inspire performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Total U.S. sales territories: 348 compared to the 356 average estimate based on two analysts.
- New U.S. sales territories: 5 compared to the 13 average estimate based on two analysts.
- Geographic Revenue- United States: $207.15 million compared to the $206.54 million average estimate based on five analysts. The reported number represents a change of +10.3% year over year.
- Geographic Revenue- All other countries: $9.94 million versus the five-analyst average estimate of $8.35 million. The reported number represents a year-over-year change of +23%.
View all Key Company Metrics for Inspire here>>>
Shares of Inspire have returned -1.9% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Inspire Medical Systems, Inc. (INSP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
